Semax (ACTH 4-10 Analog)

Chemical Name: Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP) Alternative Names: ACTH(4-10) Pro-Gly-Pro Molecular Formula: C₃₇H₅₁N₉O₁₀S Molecular Weight: 813.9 Da CAS Number: 80714-61-0 Peptide Classification: Synthetic ACTH analog with nootropic properties WADA Status: NOT CURRENTLY BANNED (as of 2025)

Goal Relevance:

• Enhance mental clarity and focus for improved productivity and concentration.
• Support memory retention and cognitive function for studying or work performance.
• Aid in recovery from brain injuries, such as concussions or strokes, to improve neurological health.
• Manage symptoms of anxiety and depression to promote emotional well-being.
• Improve attention and focus in children with ADHD for better academic performance.
• Support recovery from optic nerve diseases like glaucoma for better eye health.
• Enhance executive function for better decision-making and problem-solving skills.

1. Executive Summary

Semax is a synthetic heptapeptide (7 amino acids) derived from the adrenocorticotropic hormone (ACTH) fragment 4-10, with an added C-terminal Pro-Gly-Pro (PGP) tripeptide sequence for enhanced metabolic stability. Originally developed by the Institute of Molecular Genetics of the Russian Academy of Sciences in collaboration with Moscow State University in the 1980s, Semax has been extensively studied and clinically used in Russia for over three decades.

Structure and Origin:

• Base Sequence: ACTH(4-7) fragment: Met-Glu-His-Phe
• Stabilizing Modification: C-terminal Pro-Gly-Pro (PGP) tripeptide
• Full Sequence: Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP)
• Design Rationale: PGP addition confers resistance to enzymatic degradation, prolonging duration of action

Primary Mechanism of Action:

• Neurotrophic Modulation: Rapidly elevates BDNF (Brain-Derived Neurotrophic Factor) and NGF (Nerve Growth Factor) expression
• Neurotransmitter Enhancement: Increases dopamine and serotonin levels in key brain regions
• Neuroprotection: Protects neurons from oxidative stress, hypoxia, and ischemic damage
• Neuroplasticity: Promotes synaptic plasticity and long-term potentiation (LTP) - the cellular basis of learning and memory

Approved Clinical Uses (Russia):

1. Acute Ischemic Stroke: Neuroprotection and enhanced recovery
2. Cognitive Disorders: Memory impairment, attention deficits, cognitive decline
3. Optic Nerve Disease: Glaucoma, optic neuropathy
4. Pediatric Applications: Attention disorders in children aged 3+ (Minisem brand)

Off-Label / Experimental Uses (Western Countries):

• Nootropic cognitive enhancement (focus, memory, processing speed)
• Anxiety and depression management
• ADHD symptom mitigation
• Post-concussion or traumatic brain injury recovery
• Executive function optimization

Evidence Base:

• Over 100 published studies spanning cellular mechanisms, animal models, and human clinical trials
• Strongest evidence: Ischemic stroke recovery (multiple RCTs in Russia with 100+ patients)
• Moderate evidence: Cognitive enhancement in healthy and impaired populations
• Limited Western research: Most data from Russian institutions; minimal peer-reviewed validation outside Eastern Europe

Routes of Administration:

• Intranasal spray: Primary route; optimal bioavailability for CNS effects
• Subcutaneous injection: Alternative route for systemic delivery

Key Differentiators:

• vs. Selank: Semax is stimulating/activating (dopaminergic, focus-oriented), while Selank is calming/anxiolytic (GABAergic, stress-reducing). They are complementary rather than competitive.
• BDNF Mechanism: One of the fastest-acting BDNF elevators available, with measurable increases within 1-4 hours
• Biohacker Appeal: Acute cognitive enhancement without the crash or tolerance development seen with traditional stimulants
• Clinical Validation: Three decades of Russian pharmaceutical use provides extensive real-world safety data unavailable for most research peptides

2. Chemical Structure & Composition

2.1 Amino Acid Sequence

Full Sequence:

Met¹ - Glu² - His³ - Phe⁴ - Pro⁵ - Gly⁶ - Pro⁷
(MEHFPGP)

Structural Domains:

1. ACTH(4-7) Fragment: Met-Glu-His-Phe

   • Derived from endogenous adrenocorticotropic hormone
   • Retains melanocortin receptor activity (reduced potency vs. full ACTH)

2. Pro-Gly-Pro (PGP) Tripeptide: Pro-Gly-Pro

   • C-terminal stabilizing sequence
   • Inspired by endogenous regulatory peptides
   • Confers resistance to proteolytic degradation

2.2 Molecular Characteristics

Molecular Formula: C₃₇H₅₁N₉O₁₀S Molecular Weight: 813.9 Da (813.92 g/mol) CAS Registry Number: 80714-61-0

Key Functional Groups:

• Methionine (Met): Contains sulfur (thioether); susceptible to oxidation
• Glutamic Acid (Glu): Negatively charged acidic residue
• Histidine (His): Imidazole side chain; pH-sensitive charge
• Phenylalanine (Phe): Hydrophobic aromatic ring
• Proline (Pro) x2: Induces conformational rigidity (turn structures)
• Glycine (Gly): Small, flexible residue

Net Charge: Neutral to slightly negative at physiological pH (Glu carboxyl group)

2.3 Relationship to ACTH

Adrenocorticotropic Hormone (ACTH):

• Full Length: 39 amino acids
• Function: Stimulates cortisol release from adrenal cortex
• Fragment 4-10: Met-Glu-His-Phe-Arg-Trp-Gly (endogenous sequence)

Semax Modifications:

• Retains: Met-Glu-His-Phe core (amino acids 4-7 of ACTH)
• Omits: Arg-Trp-Gly (positions 8-10 of ACTH fragment)
• Adds: Pro-Gly-Pro C-terminal extension

Functional Consequence:

• Reduced ACTH Activity: Semax has minimal effect on cortisol secretion (lacks full melanocortin receptor agonist activity)
• Enhanced Stability: PGP tripeptide extends half-life from minutes (ACTH 4-10) to hours (Semax)
• Preserved Nootropic Effects: Cognitive enhancement properties retained without hyperstimulation of HPA axis

2.4 Synthesis

Solid-Phase Peptide Synthesis (SPPS):

1. Fmoc Chemistry: Sequential coupling of Fmoc-protected amino acids
2. Cleavage: TFA (trifluoroacetic acid) cleavage from resin
3. Purification: Reverse-phase HPLC to >95% purity
4. Lyophilization: Freeze-drying to stable powder

Quality Control:

• Mass Spectrometry: Confirm MW = 813.9 Da
• Amino Acid Analysis: Verify sequence fidelity
• HPLC Purity: Should be >95% (pharmaceutical grade >98%)
• Endotoxin Testing: <10 EU/mg for injectable formulations

Commercial Availability:

• Russia: Pharmaceutical-grade intranasal drops (0.1% and 1% solutions)
• Western Markets: Research-grade lyophilized powder (grey market)

3. Mechanism of Action

3.1 Neurotrophic Modulation

Brain-Derived Neurotrophic Factor (BDNF) - Deep Dive:

BDNF is widely considered the most important neurotrophin for cognitive function, neuroplasticity, and brain health. Semax's ability to rapidly elevate BDNF is its primary mechanism for cognitive enhancement and neuroprotection.

BDNF Elevation Mechanism:

• Effect: Semax rapidly elevates BDNF levels and expression in hippocampus and frontal cortex
• Magnitude: Rodent studies show 30-50% increase in BDNF mRNA within 1-4 hours post-administration (Inozemtseva et al., 2008)
• Mechanism: Upregulation of BDNF gene transcription via CREB (cAMP response element-binding protein) pathway
• Functional Consequence: Enhanced synaptic plasticity, neurogenesis, and long-term potentiation (LTP)
• Speed of Action: Among the fastest-acting BDNF elevators available; detectable within 1 hour
• Duration: BDNF elevation persists for 4-8 hours after single intranasal dose

What BDNF Does (Functional Impact):

1. Synaptic Plasticity: Strengthens connections between neurons, facilitating learning and memory formation
2. Neurogenesis: Promotes growth of new neurons in hippocampus (memory center)
3. Neuroprotection: Protects existing neurons from damage, oxidative stress, and apoptosis
4. Long-Term Potentiation (LTP): Enhances the cellular mechanism underlying memory consolidation
5. Dendritic Branching: Increases complexity of neuronal connections, expanding processing capacity
6. Mood Regulation: Low BDNF is implicated in depression; elevation improves mood and stress resilience

BDNF vs. Other Interventions:

Clinical Significance of BDNF Elevation:

• Cognitive Decline Prevention: Higher BDNF levels correlate with preserved cognitive function in aging
• Stroke Recovery: BDNF promotes neural repair and functional recovery after ischemic injury
• Depression Treatment: Many antidepressants work partially through BDNF upregulation
• Learning Enhancement: BDNF elevation during learning periods improves memory encoding and retention

Nerve Growth Factor (NGF):

• Effect: Increased NGF expression in hippocampus and retina
• Function: Supports neuronal survival, differentiation, and maintenance
• Clinical Relevance: NGF elevation underlies Semax's efficacy in optic nerve disorders (glaucoma, optic neuropathy)
• Synergy with BDNF: NGF and BDNF work together to support overall neuronal health and plasticity

TrkB Receptor Activation:

• Semax increases expression of tropomyosin receptor kinase B (TrkB), the primary BDNF receptor
• Enhanced BDNF-TrkB signaling drives neuroplasticity and learning/memory consolidation
• Mechanism: More receptors = greater sensitivity to BDNF = amplified neuroplastic response
• Practical Impact: This dual action (increasing BDNF + increasing BDNF receptors) creates synergistic cognitive enhancement

3.2 Neurotransmitter Systems

Dopaminergic System:

• Effect: Semax activates dopaminergic brain systems, particularly in striatum and prefrontal cortex
• Evidence: Increased dopamine metabolites (DOPAC, HVA) in rodent striatum (Eremin et al., 2006)
• Functional Outcome: Enhanced motivation, focus, reward processing

Serotonergic System:

• Effect: Rapidly activates serotonergic pathways
• Evidence: Extracellular striatal 5-HIAA (serotonin metabolite) increased by 180% within 1-4 hours after Semax administration
• Functional Outcome: Mood regulation, anxiety modulation, cognitive flexibility

Cholinergic System (Indirect):

• Semax may enhance acetylcholine signaling via neuroprotective effects on cholinergic neurons
• Evidence primarily from stroke models where cholinergic deficits are reversed

3.3 Melanocortin Receptor Activity

MC4 and MC5 Receptors:

• Evidence: Semax may act as antagonist or partial agonist at melanocortin receptors MC4 and MC5
• Functional Role: Modulation of feeding behavior, energy homeostasis, and cognitive arousal
• Clinical Relevance: Mechanism unclear; Semax does NOT significantly affect cortisol or appetite in clinical studies (unlike full ACTH)

3.4 Neuroprotective Mechanisms

Oxidative Stress Reduction:

• Antioxidant Properties: Semax reduces production of reactive oxygen species (ROS) in neurons
• Mechanism: Upregulation of endogenous antioxidant enzymes (SOD, catalase, glutathione peroxidase)
• Evidence: Stroke models show reduced lipid peroxidation and protein carbonylation

Anti-Inflammatory Effects:

• Cytokine Modulation: Reduces pro-inflammatory cytokines (IL-1β, TNF-α) in ischemic brain tissue
• Mechanism: Inhibits NF-κB pathway activation
• Evidence: Gene expression studies show predominant upregulation of immune-regulatory genes (Filippenkov et al., 2014)

Hypoxia Resistance:

• Semax protects neurons under hypoxic conditions (low oxygen)
• Mechanism: Stabilization of mitochondrial membrane potential; reduced cytochrome c release (anti-apoptotic)

Enkephalin System:

• Unique Mechanism: Semax inhibits enzymes involved in degradation of enkephalins (endogenous opioid peptides)
• Effect: Prolonged enkephalin activity → enhanced endogenous pain modulation and stress resilience

3.5 Amyloid-Beta (Aβ) Modulation

Alzheimer's Relevance:

• Finding: Semax affects copper-induced Aβ aggregation and amyloid formation in artificial membrane models (Gudasheva et al., 2022)
• Mechanism: May interfere with Aβ oligomerization and fibril formation
• Clinical Relevance: Potential therapeutic target for Alzheimer's disease (preclinical stage)

4. Goal Archetype Integration (DEEP Framework)

4.1 Primary Goal Alignment

4.2 Cognitive Optimization - Deep Dive (PRIMARY USE CASE)

Semax is fundamentally a cognitive optimization tool. Understanding the specific dimensions of cognitive enhancement is critical for proper application.

4.2.1 Cognitive Domains Enhanced by Semax

Executive Function:

• Working Memory: Ability to hold and manipulate information in mind (e.g., mental math, following complex instructions)
• Evidence: Trail Making Test improvements; digit span improvements in clinical studies
• Mechanism: Dopaminergic activation in prefrontal cortex + BDNF-mediated synaptic plasticity
• Practical Impact: Better multitasking, complex problem-solving, strategic thinking
• Onset: Days 3-7; builds over 2-4 weeks

Attention and Focus:

• Sustained Attention: Ability to maintain focus on a task over extended periods
• Selective Attention: Filtering out distractions; focusing on relevant stimuli
• Evidence: Attention span studies in healthy adults during 8-hour workday; pediatric ADHD approval in Russia
• Mechanism: Dopamine increase in striatum and prefrontal cortex
• Practical Impact: Deep work capacity, reduced distractibility, flow state access
• Onset: Days 1-3 (relatively rapid)

Processing Speed:

• Mental Velocity: How quickly you understand, integrate, and respond to information
• Evidence: Reaction time improvements in cognitive testing; subjective reports of "mental clarity"
• Mechanism: Enhanced neurotransmitter signaling efficiency; BDNF-mediated neural conductivity
• Practical Impact: Faster reading comprehension, quicker decision-making, improved verbal fluency
• Onset: Days 3-7

Memory:

• Encoding: Forming new memories (learning new information)
• Consolidation: Transferring short-term memories to long-term storage
• Recall: Retrieving stored information
• Evidence: Short-term memory improvements in healthy subjects; BDNF elevation (key for consolidation)
• Mechanism: BDNF-mediated LTP in hippocampus; enhanced synaptic strength
• Practical Impact: Better retention of studied material, improved name/face recall, enhanced spatial memory
• Onset: Weeks 2-4 (neuroplastic changes take time)

Verbal Fluency:

• Word Retrieval: Accessing vocabulary quickly and accurately
• Articulation: Expressing thoughts clearly and coherently
• Evidence: Anecdotal reports; serotonergic activation supports verbal processing
• Mechanism: Enhanced prefrontal-temporal connectivity; dopamine/serotonin modulation
• Practical Impact: Improved public speaking, faster writing, better conversation flow
• Onset: Days 3-7

4.2.2 Application by Cognitive Goal Archetype

Archetype 1: The Knowledge Worker (Productivity/Focus)

• Profile: Software developer, analyst, writer, consultant
• Primary Need: Sustained focus, processing speed, mental stamina
• Semax Protocol:
  • Dose: 600 mcg/day (300 mcg AM + 300 mcg early PM)
  • Cycle: 30 days on, 7 days off
  • Stack: Semax + caffeine + L-theanine (for smooth focus)
  • Timing: Dose before deep work blocks (morning + post-lunch)
• Expected Outcome: 20-40% increase in productive work hours; reduced mental fatigue; better flow state access
• Monitoring: Daily productivity tracking; subjective focus ratings (1-10 scale)

Archetype 2: The Student (Learning/Memory)

• Profile: University student, medical resident, professional certification seeker
• Primary Need: Memory encoding, retention, recall; exam performance
• Semax Protocol:
  • Dose: 600-900 mcg/day (300 mcg AM + 300 mcg midday + 300 mcg early PM)
  • Cycle: 30 days leading up to exams; 7-14 days off after
  • Stack: Semax + racetams (piracetam 4,800 mg/day) + choline (alpha-GPC 300 mg)
  • Timing: Dose during study sessions to leverage BDNF elevation during learning
• Expected Outcome: Improved information retention; faster learning curves; better recall under exam pressure
• Monitoring: Practice test scores; flashcard retention rates; subjective memory assessment

Archetype 3: The Executive (Decision-Making/Strategic Thinking)

• Profile: C-suite, manager, entrepreneur, investor
• Primary Need: Executive function, strategic thinking, decision quality, stress resilience under high stakes
• Semax Protocol:
  • Dose: 600 mcg/day Semax + 600 mcg/day Selank (combined stack for cognitive enhancement + stress buffering)
  • Cycle: 30 days on, 7 days off
  • Stack: Semax + Selank (primary); optionally + modafinil (low dose) on critical days
  • Timing: AM dose before strategy sessions; midday dose before high-stakes meetings
• Expected Outcome: Improved decision quality; enhanced pattern recognition; better risk assessment; reduced decision fatigue
• Monitoring: Decision journal; post-decision analysis; stress/anxiety ratings

Archetype 4: The Aging Professional (Cognitive Preservation)

• Profile: 50+ individual seeking to maintain mental acuity; prevent cognitive decline
• Primary Need: Neuroprotection, BDNF elevation, maintenance of processing speed and memory
• Semax Protocol:
  • Dose: 400-600 mcg/day (lower dose due to increased CNS sensitivity with age)
  • Cycle: 30 days on, 7-10 days off
  • Stack: Semax + omega-3 (2g EPA/DHA daily) + Lion's Mane (1g daily)
  • Timing: Morning dose; avoid afternoon to minimize sleep interference
• Expected Outcome: Preserved cognitive function; subjective improvements in mental clarity; potential long-term neuroprotection
• Monitoring: Quarterly cognitive assessments (MoCA, Trail Making Test); BDNF testing (optional)

Archetype 5: The Biohacker (Performance Optimization)

• Profile: Quantified self enthusiast, competitive edge-seeker, nootropic experimenter
• Primary Need: Maximum cognitive enhancement; trackable metrics; experimentation
• Semax Protocol:
  • Dose: Start 600 mcg/day; titrate up to 900 mcg/day based on response
  • Cycle: 30 days on, 7 days off; experiment with longer cycles (60 days) and different variants
  • Stack: Semax + Selank + racetams + choline + caffeine + L-theanine (comprehensive stack)
  • Timing: Optimize based on cognitive testing; experiment with pre-workout cognitive enhancement
• Expected Outcome: Measurable cognitive performance gains; optimized personal protocol; detailed response data
• Monitoring: Full cognitive battery (Cambridge Brain Sciences); daily tracking (Lumosity); optional BDNF testing; heart rate variability (stress marker)

4.3 Neuroprotection Goal Alignment

Profile: Individuals concerned with brain health, aging, cognitive decline prevention, or recovering from neurological insults

Primary Applications:

1. Stroke Recovery (Strongest Evidence)
2. Traumatic Brain Injury (TBI) / Post-Concussion
3. Age-Related Cognitive Decline Prevention
4. Neurodegenerative Disease Risk Reduction

Neuroprotective Mechanisms:

• Oxidative stress reduction (antioxidant enzyme upregulation)
• Anti-inflammatory effects (cytokine modulation)
• Hypoxia resistance (mitochondrial protection)
• BDNF-mediated neuronal survival
• Potential amyloid-beta aggregation interference (Alzheimer's relevance)

Protocol for Neuroprotection:

• Dose: 600-900 mcg/day (moderate to high)
• Duration: Longer cycles (60 days on, 14 days off) or quasi-continuous use (5 days on, 2 days off weekly)
• Monitoring: Cognitive assessments quarterly; neurologist follow-up for clinical conditions
• Stack: Combine with omega-3, curcumin, NAD+ precursors (NMN/NR), exercise

4.4 Recovery Goal Alignment

Profile: Individuals recovering from acute neurological injury or seeking enhanced neural repair

Primary Applications:

1. Acute Ischemic Stroke (Approved in Russia)
2. Traumatic Brain Injury (TBI)
3. Post-Concussion Syndrome
4. Optic Nerve Damage (glaucoma, optic neuropathy)

Recovery Mechanisms:

• BDNF/NGF elevation promotes neural repair and regeneration
• Angiogenesis (new blood vessel formation) in damaged tissue
• Anti-inflammatory effects reduce secondary injury cascade
• Neuroplasticity enhancement supports functional reorganization

Protocol for Recovery (Clinical Supervision Required):

• Dose: 3,000-6,000 mcg/day (high-dose; 1% intranasal solution or IV in hospital settings)
• Duration: 10-14 days acute phase; may repeat after 20-day interval
• Route: Intranasal 1% solution (for stroke/TBI); standard 0.1% for optic nerve conditions
• Monitoring: Neurological assessments; imaging as indicated; functional recovery scales (Barthel Index for stroke)
• Medical Supervision: Required for high-dose protocols; coordinate with neurologist

4.5 Performance Optimization

Profile: High performers seeking competitive edge in cognitively demanding fields (athletics requiring split-second decisions, competitive gaming, trading, etc.)

Primary Applications:

• Mental performance in high-stakes environments
• Split-second decision-making (e.g., gaming, trading, tactical operations)
• Learning complex motor-cognitive skills (e.g., competitive sports)
• Sustained high-level cognitive output

Performance Enhancement Mechanisms:

• Dopaminergic activation improves motivation, drive, reward sensitivity
• Processing speed enhancement supports rapid decision-making
• BDNF elevation supports skill acquisition and motor learning

Protocol for Performance:

• Dose: 600-900 mcg/day
• Timing: Pre-performance dosing (60-90 minutes before competition/high-stakes event)
• Cycle: Event-based cycles (2 weeks leading up to competition + day-of; then off-cycle)
• Stack: Semax + caffeine + creatine (for cognitive performance)
• Caution: Verify WADA status for competitive athletes (currently not banned as of 2025, but subject to change)

4.6 When Semax Makes Sense (Expanded)

Ideal Candidates:

• Knowledge workers with high cognitive demands (software engineering, analysis, writing)
• Students during exam preparation or intensive learning periods
• Executives making high-stakes decisions under stress (when stacked with Selank)
• Individuals 50+ seeking cognitive preservation and neuroprotection
• Post-stroke or TBI patients (under medical supervision; approved in Russia)
• Individuals with optic nerve disorders (glaucoma, optic neuropathy)
• ADHD symptom management (off-label in West; approved for pediatrics in Russia)
• Biohackers seeking trackable cognitive enhancement

Situational Use:

• Exam preparation (2-4 week pre-exam cycle)
• Major project deadlines (3-4 week intensive work cycle)
• Learning new complex skills (programming language, medical procedures, etc.)
• Public speaking preparation (1-2 week cycle)
• High-stress professional periods (quarterly earnings, product launches)

4.7 When to Choose Something Else (Expanded)

4.8 Semax vs. Selank - Comprehensive Comparison

The Russian Nootropic Duo: Semax and Selank are both Russian-developed peptides, both derived from endogenous peptide fragments, and both approved as pharmaceuticals in Russia. However, they have fundamentally different mechanisms and applications.

When to Use Semax Alone:

• Primary goal is cognitive performance, learning, memory
• Baseline anxiety is low to moderate
• Seeking activating, energizing cognitive enhancement
• Focus and productivity are limiting factors
• Comfortable with mild stimulation

When to Use Selank Alone:

• Primary goal is anxiety reduction, stress management
• Baseline anxiety is moderate to high
• Seeking calm, relaxed state without sedation
• Social anxiety or performance anxiety is present
• Prefer non-stimulating cognitive support

When to Stack Semax + Selank (BEST FOR MOST USERS):

• Primary goal is balanced cognitive enhancement (focus + stress resilience)
• Demanding work environment with high cognitive load AND high stress
• Sensitive to stimulant-induced anxiety but need cognitive boost
• Seeking "calm productivity" rather than "driven intensity"
• Executive function under pressure (high-stakes decisions)
• This is the most common protocol in Russian clinical practice and Western biohacking

Stacking Ratio:

• Balanced: 1:1 ratio (e.g., 600 mcg Semax + 600 mcg Selank daily)
• Focus-Dominant: 2:1 ratio (e.g., 600 mcg Semax + 300 mcg Selank daily)
• Anxiety-Dominant: 1:2 ratio (e.g., 300 mcg Semax + 600 mcg Selank daily)

Practical Decision Tree:

Is your primary goal cognitive enhancement or anxiety reduction?

Cognitive Enhancement → Is baseline anxiety low?
    Yes → Semax alone
    No → Semax + Selank stack

Anxiety Reduction → Do you also need cognitive boost?
    Yes → Selank + Semax stack
    No → Selank alone

Balanced Performance (productivity + stress resilience)?
    → Semax + Selank stack (1:1 ratio)

5. Pharmacokinetics and Metabolism

4.1 Absorption and Bioavailability

Intranasal Administration (Primary Route):

• Absorption: Direct nose-to-brain transport via olfactory and trigeminal nerve pathways
• Bioavailability: ~60-70% reaches CNS (bypasses blood-brain barrier limitations of systemic administration)
• Tmax: 15-30 minutes (peak CNS concentration)
• Advantages:
  • Non-invasive
  • Rapid onset
  • Avoids first-pass hepatic metabolism
  • Higher CNS bioavailability vs. oral/SC routes

Subcutaneous Injection:

• Bioavailability: ~50-60% (systemic circulation)
• Tmax: 30-60 minutes
• Disadvantages: Lower CNS penetration compared to intranasal (must cross blood-brain barrier)

Oral Administration:

• Bioavailability: Negligible (<5%)
• Reason: Gastrointestinal proteolytic degradation
• Not Recommended: Ineffective route for Semax

4.2 Distribution

• Volume of Distribution (Vd): Limited data; estimated ~0.2-0.4 L/kg
• Protein Binding: Low (<20%); circulates primarily as free peptide
• CNS Penetration: Intranasal administration achieves 10-fold higher CNS concentrations vs. IV injection (rodent studies)

4.3 Metabolism and Elimination

Half-Life:

• Native ACTH(4-10): ~5-10 minutes (rapid proteolytic degradation)
• Semax: ~1-2 hours (Pro-Gly-Pro stabilization extends half-life)

Metabolic Pathways:

• Proteolytic Cleavage: Plasma peptidases (dipeptidyl peptidase-IV, aminopeptidases) cleave peptide bonds
• Primary Degradation: N-terminal methionine oxidation and Glu-His bond cleavage

Excretion:

• Renal Clearance: Glomerular filtration of intact peptide and fragments
• Fecal Clearance: Minimal

Clinical Implication: Short half-life necessitates 2-3 times daily dosing for sustained nootropic effects.

5. Dosing Protocols and Administration

5.1 Dosing by Application (Goal-Specific Protocols)

5.1.1 Productivity and Focus (Knowledge Workers, Developers, Writers)

Objective: Sustained attention, mental stamina, processing speed for 6-10 hour work blocks

Protocol:

• Dose: 600 mcg/day (300 mcg AM + 300 mcg early afternoon)
• Timing:
  • First dose: 30-60 minutes after waking, before morning work block
  • Second dose: 4-6 hours after first dose (typically 12-2 PM before afternoon work)
• Cycle: 30 days on, 7 days off
• Monitoring: Daily productivity hours logged; subjective focus rating (1-10)
• Optimization: If insufficient, increase to 900 mcg/day (300 mcg x 3 doses); if overstimulating, reduce to 400 mcg/day

Stack Additions:

• Caffeine 100-200 mg (synergistic focus)
• L-Theanine 200 mg (smooths stimulation)
• Optional: Alpha-GPC 300 mg (choline support for sustained cognition)

5.1.2 Learning and Memory (Students, Exam Preparation)

Objective: Enhanced memory encoding, retention, recall; improved study efficiency

Protocol:

• Dose: 600-900 mcg/day (300 mcg AM + 300 mcg midday + 300 mcg early evening)
• Timing:
  • Dose during or immediately before study sessions to leverage BDNF elevation during learning
  • Space doses 4-6 hours apart to maintain elevated BDNF throughout study day
• Cycle: Begin 2-4 weeks before exam period; continue through exams; 7-14 day break after
• Monitoring: Practice test scores; flashcard retention percentage; subjective recall assessment
• CRITICAL: Last dose no later than 4 PM to avoid sleep interference

Stack Additions:

• Piracetam 1,600 mg 3x/day (cholinergic enhancement)
• Alpha-GPC 300-600 mg/day (choline support for racetam synergy)
• Optional: Bacopa monnieri 300 mg/day (memory consolidation support)

5.1.3 Neuroprotection (Age 50+ Cognitive Preservation)

Objective: Preserve cognitive function, prevent decline, chronic BDNF elevation for brain health

Protocol:

• Dose: 400-600 mcg/day (reduced dose for increased CNS sensitivity with age)
  • Age 50-65: 600 mcg/day (300 mcg AM + 300 mcg midday)
  • Age 65+: 400 mcg/day (200 mcg AM + 200 mcg midday) - start lower
• Timing: Morning dose only, or split AM/midday; avoid afternoon dosing (sleep sensitivity increases with age)
• Cycle: Longer cycles (60 days on, 14 days off) or quasi-continuous (5 days on, 2 days off weekly)
• Monitoring: Quarterly cognitive assessment (MoCA, Trail Making Test); annual neuropsych evaluation

Stack Additions:

• Omega-3 (EPA/DHA) 2-3 g/day (brain health foundation)
• Lion's Mane 1,000 mg/day (NGF support)
• NAD+ precursor (NMN 250-500 mg or NR 300 mg)
• Aerobic exercise 150 min/week (BDNF synergy)

5.1.4 Stroke/TBI Recovery (Clinical Supervision Required)

Objective: Accelerate neurological recovery, reduce secondary injury, promote neural repair

Protocol:

• Dose: 3,000-6,000 mcg/day (HIGH DOSE - requires 1% intranasal solution or IV)
  • Stroke (Russian clinical protocol): 6,000 mcg/day for 10 days; repeat after 20-day interval
  • TBI/Concussion: 3,000-4,000 mcg/day for 7-14 days
• Route: Intranasal 1% solution (preferred) or IV administration (hospital setting)
• Timing: Divided into 3-4 doses throughout day (e.g., 2,000 mcg x 3 doses)
• Duration: Acute phase 10-14 days; may extend or repeat cycles based on neurological recovery
• Monitoring: Neurological examination; functional recovery scales (Barthel Index, mRS); MRI/CT as indicated
• Medical Supervision: REQUIRED - coordinate with neurologist

Evidence: Multiple Russian RCTs in stroke patients; BDNF elevation correlates with improved recovery

5.1.5 ADHD Symptom Management (Off-Label)

Objective: Improve attention, reduce impulsivity, enhance executive function

Adults:

• Dose: 600-900 mcg/day (300 mcg AM + 300 mcg midday + optional 300 mcg early afternoon)
• Timing: Before cognitively demanding tasks; avoid late afternoon/evening
• Cycle: 30 days on, 7 days off
• Monitoring: ADHD symptom scales (ASRS-v1.1); work/academic performance metrics

Pediatrics (Age 7-18, based on Russian Minisem approval for age 3+):

• Dose: 200-400 mcg/day (weight-based: ~3-6 mcg/kg/day)
• Product: Minisem (low-dose pediatric formulation in Russia)
• Frequency: 2 divided doses (AM + midday)
• Duration: 30 days; reassess with pediatrician
• CRITICAL: Pediatric use requires physician supervision; not FDA-approved in USA

Stack Considerations:

• If already on stimulants (Adderall, Ritalin): Reduce Semax dose by 50%; monitor for overstimulation
• Consider Semax as alternative to stimulants (trial period with physician oversight)

5.1.6 Acute Performance (Exams, Presentations, High-Stakes Events)

Objective: Maximize cognitive performance for single event or short period (3-7 days)

Protocol:

• Dose: 600-900 mcg on performance day (300 mcg 90 min before event + 300 mcg 4 hours before if multi-day)
• Lead-In: Optional 3-5 day loading (600 mcg/day) before main event
• Timing: Peak effects 60-90 minutes post-dose; plan accordingly
• Cycle: Event-based; 7-14 day washout before next use
• Monitoring: Performance outcomes; subjective assessment of clarity/focus

Example - Exam Day:

• 7:00 AM: 300 mcg Semax + 100 mg caffeine
• 9:00 AM: Exam begins (peak Semax effect)
• 12:00 PM: 300 mcg Semax booster (if afternoon exam continues)

5.2 Intranasal Administration (Primary Route)

Standard 0.1% Semax Solution (1 mg/mL):

Cognitive Enhancement / Nootropic Use:

• Dose: 400-900 mcg per day
• Frequency: Divided into 2-3 doses (e.g., 300 mcg morning + 300 mcg afternoon + 300 mcg evening)
• Duration: 14-30 days continuous use
• Cycle Strategy: 30 days on / 7-14 days off

Mental Exhaustion / Acute Stress:

• Dose: 400-900 mcg per day
• Frequency: 2-3 divided doses
• Duration: 3-5 days (short-term intervention)

Mild Cognitive Impairment (Children/Adolescents):

• Dose: 200-400 mcg per day (lower dose for pediatric use)
• Frequency: 2 divided doses
• Duration: 30 days
• Product: Minisem (approved in Russia for ages 3+)

Optic Nerve Disorders (Glaucoma, Optic Neuropathy):

• Dose: 600-900 mcg per day
• Frequency: 2-3 divided doses
• Duration: 7-10 days

High-Dose 1% Semax Solution (10 mg/mL) - Neurological Conditions:

Acute Ischemic Stroke (Clinical Protocol):

• Dose: 6,000 mcg per day (6 mg/day)
• Duration: 10 days
• Cycle: Two courses with 20-day interval (total 40 days of treatment over 50 days)
• Evidence: RCT in 110 stroke patients showed improved motor recovery and BDNF levels (Stroke Trial, Russia)

Traumatic Brain Injury / Severe Cognitive Impairment:

• Dose: 3,000-6,000 mcg per day
• Duration: 5-10 days (acute phase)
• Route: Intranasal 1% solution or IV administration (hospital setting)

5.2 Subcutaneous Injection

Dosing:

• Typical Range: 500-1,000 mcg per day
• Frequency: 1-2 injections daily
• Cycle Length: 4-8 weeks continuous use

Reconstitution (Lyophilized Powder):

1. Add 2.5 mL bacteriostatic water to 25 mg Semax vial
2. Concentration: 10 mg/mL (10,000 mcg/mL)
3. For 500 mcg dose: Draw 0.05 mL (5 units on insulin syringe)

Injection Technique:

• Sites: Abdomen, thighs (standard subcutaneous sites)
• Needle: 29-31 gauge, 0.5 inch (insulin syringe)
• Rotation: Rotate sites to prevent lipodystrophy

5.3 Intranasal Spray Administration Technique

Step-by-Step:

1. Clear Nasal Passages: Gently blow nose before administration
2. Prime Pump: First use requires 3-5 pumps to prime (discard these doses)
3. Positioning: Tilt head slightly forward (not backward)
4. Administration:
   • Close one nostril
   • Insert spray nozzle into open nostril (aim toward outer wall, not septum)
   • Press pump while inhaling gently
   • Sniff lightly after spray (do NOT sniff forcefully)
5. Repeat: Alternate nostrils for multiple sprays

Dosage per Spray:

• 0.1% Solution: ~50-100 mcg per spray (manufacturer-dependent)
• 1% Solution: ~500-1,000 mcg per spray

Storage: Refrigerate opened intranasal bottles at 2-8°C; use within 30 days

5.4 Timing Strategies

Morning Administration (Optimal for Cognitive Enhancement):

• Rationale: Aligns with peak cortisol rhythm; enhances daytime alertness and focus
• Protocol: First dose within 30-60 minutes of waking

Afternoon Booster:

• Rationale: Sustains cognitive performance during afternoon productivity dip
• Protocol: Second dose 4-6 hours after morning dose

Avoid Evening Dosing:

• Reason: Mild stimulatory effects may interfere with sleep onset
• Recommendation: Last dose no later than 3-4 hours before bedtime

5.5 Age-Stratified Dosing (Intranasal) - Comprehensive

5.5.1 Pediatric Dosing (Russian Clinical Guidelines)

CRITICAL: Pediatric use should only occur under physician supervision. Semax is approved for pediatric use in Russia (Minisem brand) but NOT FDA-approved in USA.

Pediatric Weight-Based Dosing:

• Conservative: 3-5 mcg/kg/day (divided into 2 doses)
• Moderate: 5-7 mcg/kg/day (for therapeutic applications; physician-supervised)
• Example: 40 kg child = 120-280 mcg/day (split AM/midday)

Pediatric Safety Monitoring:

• Behavior changes (irritability, hyperactivity, or unusual calmness)
• Sleep patterns (difficulty falling asleep may indicate late dosing or sensitivity)
• Academic/cognitive performance (tracking efficacy)
• Growth and development (no growth impact expected, but monitor)
• Coordination with school (teacher feedback on attention/behavior)

When to Avoid Pediatric Use:

• Severe anxiety in child (may worsen)
• Sleep disorders (may exacerbate)
• Cardiovascular abnormalities (lack of safety data)
• Uncontrolled diabetes (may affect glucose)

5.5.2 Adult Dosing by Age (Detailed)

Ages 18-35 (Young Adults):

Ages 35-50 (Middle Age):

Ages 50-65 (Early Seniors):

Physiological Changes Age 50-65:

• Dopamine receptor density decreases (~10% per decade after 40)
• Paradoxically increased sensitivity to dopaminergic drugs (fewer receptors = receptor upregulation)
• Sleep architecture changes (lighter sleep, easier to disrupt)
• Blood-brain barrier becomes more permeable (higher CNS drug levels from same dose)
• Renal function declines (~1% per year after 40) → slower peptide clearance

Ages 65+ (Seniors):

Physiological Changes Age 65+:

• Further dopamine system decline (risk of Parkinsonian symptoms if dopamine depleted, but also paradoxical sensitivity)
• Increased baseline anxiety and sleep fragmentation
• Polypharmacy common (interaction risk increases)
• Cognitive reserve depletion (BDNF elevation more critical)
• Cardiovascular changes (monitor if any CV disease present)

Age-Related Adjustment Decision Tree:

Age 18-35:
  Standard dosing (600-900 mcg/day) → Titrate up if needed → Monitor anxiety

Age 35-50:
  Standard dosing (600 mcg/day) → Cautious titration → Monitor sleep quality

Age 50-65:
  Start lower (400-600 mcg/day) → Slow titration → Avoid afternoon dosing → Monitor anxiety + sleep

Age 65+:
  Start low (300-400 mcg/day) → Very slow titration → Single AM dose preferred → Close monitoring → Physician coordination

5.6 Sex-Specific Considerations (Comprehensive)

5.6.1 Males

Baseline Pharmacokinetics:

• No significant sex-based pharmacokinetic differences in Semax metabolism documented in literature
• Dopamine system: Males typically have higher baseline dopamine activity (slight advantage for dopaminergic drugs)
• Standard dosing applies without modification for most men

Special Considerations:

Testosterone Replacement Therapy (TRT):

• Interaction Mechanism: Both TRT and Semax increase dopamine receptor sensitivity and dopaminergic tone
• Clinical Significance: Additive effects may lead to overstimulation, anxiety, or insomnia
• Dosing Adjustment: If on TRT, start Semax at 50-75% standard dose (e.g., 400 mcg instead of 600 mcg)
• Monitoring: Track anxiety levels, sleep quality, libido (can be overstimulated), aggression/irritability
• Timing: Some users report best results dosing Semax on opposite schedule from testosterone injection (e.g., if injecting T Monday/Thursday, use Semax Tuesday-Saturday)

Finasteride/Dutasteride (5-alpha reductase inhibitors for hair loss):

• No known direct interaction
• However, some men on finasteride report neuropsychiatric effects (anxiety, depression) → monitor closely if combining with Semax
• Consider avoiding Semax if experiencing "post-finasteride syndrome" (risk of exacerbating anxiety)

Performance Enhancement (Athletic/Competitive):

• Men more likely to use Semax for competitive edge (gaming, trading, athletics)
• Verify WADA status for competitive sports (currently not banned as of 2025)
• No anabolic effects; purely cognitive/neuroprotective

5.6.2 Females

Baseline Pharmacokinetics:

• No significant sex-based pharmacokinetic differences documented
• Dopamine system: Females may have slightly higher baseline serotonin activity and lower dopamine (theoretical, not clinically significant for dosing)
• Standard dosing applies without modification for most women

Menstrual Cycle Considerations:

Current Evidence:

• No published studies document cycle-dependent effects of Semax
• Anecdotally, some women report variable response across cycle phases

Theoretical Considerations (Based on Neurotransmitter Cycling):

Practical Approach:

• Most women: Use standard dosing throughout cycle; adjust based on subjective response
• Cycle-sensitive women: Track response across 2-3 cycles; adjust dose in luteal/premenstrual phase if needed
• PMS/PMDD: Consider Semax + Selank stack during luteal phase (Selank buffers mood/anxiety variability)

Hormonal Contraceptives:

• No known pharmacokinetic interactions with oral contraceptives, IUDs, or implants
• Hormonal contraceptives flatten natural hormonal cycling → more consistent Semax response expected
• Standard dosing applies

Pregnancy and Breastfeeding:

• CONTRAINDICATED - insufficient safety data
• No human studies in pregnant/breastfeeding women
• Unknown if Semax crosses placenta or enters breast milk
• Dopaminergic effects theoretically could affect fetal brain development
• Recommendation: Discontinue Semax if pregnancy suspected; use alternative cognitive support (omega-3, choline, adequate sleep)

Menopause/Perimenopause:

• Declining estrogen → decreased dopamine receptor sensitivity → may need higher Semax dose for same effect
• Sleep disturbances common in menopause → avoid afternoon Semax dosing
• Hot flashes: No known interaction; Semax does not affect vasomotor symptoms
• Cognitive decline in menopause: Semax may be particularly beneficial (BDNF neuroprotection)
• Dosing: Start standard dose (600 mcg/day); may need to increase to 800-900 mcg for optimal benefit

Polycystic Ovary Syndrome (PCOS):

• PCOS often associated with insulin resistance → monitor glucose closely if using Semax (7.4% of diabetics have glucose elevation)
• No direct interaction with metformin (common PCOS treatment)
• Standard dosing applies

5.7 Marker-Based Dosing (Precision Approach)

This section provides dosing adjustments based on baseline biomarkers, health conditions, and individual physiology.

5.7.1 Baseline Glucose and Metabolic Markers

Fasting Glucose <100 mg/dL (Normal):

• Standard dosing (600-900 mcg/day)
• No glucose monitoring required beyond annual physical
• Low risk of metabolic side effects

Fasting Glucose 100-125 mg/dL (Prediabetes):

• Start at 50% standard dose (300-400 mcg/day)
• Monitor fasting glucose weekly for first month
• If glucose increases >10 mg/dL from baseline → reduce dose or discontinue
• If glucose stable → cautiously increase to standard dose
• HbA1c monitoring: Check at baseline and 3 months
• Alternative: Use shorter cycles (14 days on, 7 days off) to minimize metabolic stress

Fasting Glucose >126 mg/dL (Type 2 Diabetes):

• Use with caution; medical supervision recommended
• Start at 50% standard dose (300 mcg/day)
• Daily glucose monitoring for first 2 weeks
• Coordinate with endocrinologist; may need diabetes medication adjustment
• 7.4% of diabetics experience glucose elevation on Semax (Russian data)
• If glucose increases >15% from baseline → discontinue Semax
• Risk-Benefit: Neuroprotective benefits may outweigh glucose risk in diabetic neuropathy, but requires close management

HbA1c Adjustment Table:

5.7.2 Baseline Anxiety and Mood Markers

Low Baseline Anxiety (GAD-7 score <5):

• Standard dosing (600-900 mcg/day)
• Semax alone is appropriate
• Low risk of anxiety exacerbation

Mild-Moderate Anxiety (GAD-7 score 5-14):

• Option 1: Start Semax at standard dose; monitor closely for anxiety increase
• Option 2 (Preferred): Use Semax + Selank stack from onset (600 mcg Semax + 600 mcg Selank)
• If anxiety increases on Semax alone → add Selank or reduce Semax dose 30%
• Avoid Semax if anxiety worsens despite adjustments

Moderate-Severe Anxiety (GAD-7 score >15):

• Avoid Semax alone
• Option 1: Use Selank alone (anxiolytic-first approach)
• Option 2: Use low-dose Semax + higher-dose Selank (300 mcg Semax + 900-1200 mcg Selank)
• Medical supervision recommended; coordinate with psychiatrist if on anxiolytics

Depression (PHQ-9 score):

On SSRIs/SNRIs:

• Start Semax at 50% dose (300 mcg/day) due to additive serotonergic effects
• Monitor for serotonin syndrome symptoms (agitation, confusion, rapid heart rate, dilated pupils)
• Theoretical risk of serotonin excess (Semax increases serotonin by ~180%)
• If combining, use conservative dosing and close monitoring
• Coordinate with prescribing psychiatrist

5.7.3 Cardiovascular and Blood Pressure Markers

Normal Blood Pressure (<120/80 mmHg):

• Standard dosing
• No cardiovascular monitoring beyond routine physicals

Elevated Blood Pressure (120-129/<80 mmHg):

• Standard dosing acceptable
• Monitor BP weekly for first month (Semax has no documented pressor effects, but monitor due to dopaminergic activation)

Stage 1 Hypertension (130-139/80-89 mmHg):

• Standard dosing acceptable if hypertension controlled with medications
• Coordinate with cardiologist if newly diagnosed
• Weekly BP monitoring for first month

Stage 2 Hypertension (>140/90 mmHg):

• Use with caution
• Medical supervision recommended
• No direct pressor effects documented, but dopaminergic activation theoretically could affect BP in sensitive individuals
• Ensure hypertension is controlled before initiating Semax

Cardiovascular Disease (History of MI, CHF, Arrhythmia):

• Consult cardiologist before use
• Limited safety data in cardiovascular disease populations
• Dopaminergic effects theoretically could affect heart rate/rhythm
• If approved by cardiologist: start low dose (300 mcg/day); monitor closely

5.7.4 Cognitive Baseline and Response Markers

Baseline Cognitive Function:

Response-Based Dose Adjustment:

Week 2 Assessment:

• Strong positive response (subjective focus/clarity significantly improved): Continue current dose
• Moderate response (some improvement): Increase dose 25-50%
• No response (no perceived benefit): Increase dose 50% OR verify product quality OR consider non-responder status
• Adverse response (anxiety, insomnia): Reduce dose 30-50% OR add Selank OR discontinue

5.7.5 Sleep Quality Markers

Good Sleep (PSQI score <5):

• Standard dosing
• Last dose by 2-3 PM to avoid sleep interference

Mild Sleep Issues (PSQI 5-10):

• Standard dosing BUT strict cutoff: last dose by 1 PM
• Monitor sleep latency (time to fall asleep)
• If sleep worsens → move last dose earlier or reduce to single AM dose

Moderate-Severe Insomnia (PSQI >10):

• Single morning dose only (400-600 mcg AM)
• Avoid Semax if insomnia uncontrolled
• Consider addressing sleep first before adding stimulating nootropics
• Alternative: Use Selank (anxiolytic; sleep-neutral) instead

Sleep Monitoring Protocol:

• Track sleep latency (minutes to fall asleep)
• Track wake time (time of final awakening)
• If sleep latency increases >20 minutes from baseline → adjust Semax timing or dose
• If wake time advances >30 minutes (waking too early) → reduce dose or eliminate afternoon dose

5.7 Semax Variant Comparison

Variant Selection:

• Regular Semax: Best studied; most clinical data from Russia
• N-Acetyl Semax: More energizing; longer duration; requires dose reduction
• N-Acetyl Semax Amidate: Most stable; smoother effect profile; best for once-daily dosing

6. Clinical Research & Evidence

6.1 Stroke Recovery - Strongest Evidence

6.1.1 Ischemic Stroke RCT (110 Patients)

Study: Efficacy of Semax in treatment of patients at different stages of ischemic stroke. Russian multicenter trial.

Design:

• Randomized controlled trial
• n=110 ischemic stroke patients
• Treatment: Semax 6,000 mcg/day intranasal for 10 days (two courses with 20-day interval)
• Control: Standard rehabilitation alone

Results:

• BDNF Levels: Significant increase in plasma BDNF in Semax group
• Motor Function: Improved Barthel Index scores (activities of daily living)
• Functional Recovery: Early rehabilitation + Semax accelerated recovery vs. rehabilitation alone
• Safety: No serious adverse events attributable to Semax

Conclusion: Semax enhances stroke recovery when combined with standard rehabilitation.

6.1.2 Mechanisms of Neuroprotection in Acute Stroke

Study: Investigation of mechanisms of neuro-protective effect of semax in acute period of ischemic stroke. Zhurnal Nevrologii i Psikhiatrii Imeni SS Korsakova 1999.

Findings:

• Semax activated anti-inflammatory post-ischemic reactions in brain
• Reduced infarct volume in animal models
• Improved neurological outcomes in human acute stroke patients

6.2 Cognitive Enhancement Studies

6.2.1 Healthy Adults - Attention and Memory (1996)

Study: Effects of Semax on attention span and short-term memory in healthy subjects during 8-hour workday.

Design:

• n=24 healthy adults
• Dose: 250-1,000 mcg/kg Semax (intranasal)
• Assessment: Pre- and post-shift cognitive testing

Results:

• Increased attention span and short-term memory performance
• Effects more prominent after shift completion (when exhaustion/fatigue inevitable)
• Dose-dependent response (higher doses = greater effect)

Conclusion: Semax mitigates cognitive fatigue in healthy individuals.

6.2.2 Functional MRI Study (24 Healthy Subjects)

Study: Pilot study using intranasal 1% Semax solution (1.2 mg total dose) with resting fMRI.

Findings:

• Increased resting fMRI signal in default mode network (DMN)
• DMN alterations associated with enhanced cognitive processing and memory consolidation
• No adverse effects reported

6.3 Glaucoma and Optic Nerve Disease

Study: Safety and efficacy in 36 glaucoma patients.

Design:

• n=36 patients with glaucoma
• Treatment: Semax intranasal drops for 1 month
• Outcome: Optic nerve function, intraocular pressure, adverse events

Results:

• No adverse effects after 1-month treatment
• Improved optic nerve function markers
• No significant effect on intraocular pressure (IOP)

Conclusion: Semax is safe and may provide neuroprotection in glaucoma.

6.4 Anxiety and Depression - Preclinical Evidence

6.4.1 Chronic Unpredictable Stress Model (Rats)

Study: Antidepressant-like and antistress effects of ACTH(4-10) synthetic analogs Semax. European Journal of Pharmacology 2024.

Design:

• Rat model of chronic unpredictable stress (CUS)
• Treatment: Chronic Semax administration
• Outcomes: Anhedonia (sucrose preference), hippocampal BDNF levels

Results:

• Reversed or substantially attenuated stress-induced anhedonia
• Normalized hippocampal BDNF decreases caused by chronic stress
• Antidepressant-like effects comparable to conventional antidepressants

6.4.2 Anxiolytic Effects in CCK-4 Model

Study: Effects of Semax on anxiety induced by CCK-4 (cholecystokinin tetrapeptide) in rats.

Findings:

• Semax had no effect in normal (non-anxious) state
• Normalized disrupted behavior when anxiety was induced by CCK-4
• Suggests anxiolytic properties emerge when anxiety/depression levels are elevated

6.5 BDNF and Neurotrophic Effects

Study: Comparison of temporal dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action. Journal of Molecular Neuroscience 2009.

Findings:

• Rapid BDNF upregulation: 30-50% increase in BDNF mRNA within 1-4 hours
• NGF upregulation: Parallel increase in nerve growth factor expression
• Region-Specific: Strongest effects in hippocampus (memory center) and frontal cortex (executive function)

Implication: BDNF elevation underlies Semax's pro-cognitive and neuroprotective effects.

6.6 Gene Expression Profiling in Ischemia

Study: The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis. BMC Genomics 2014.

Findings:

• Immune system genes: Predominantly upregulated (anti-inflammatory bias)
• Vascular genes: Enhanced angiogenesis and vascular remodeling
• Neuroprotective genes: Upregulation of anti-apoptotic pathways

Conclusion: Semax exerts multi-system neuroprotective effects beyond neurotrophins.

7. Safety Profile and Adverse Events

7.1 Clinical Trial Safety Data

Overall Assessment: Semax is considered well-tolerated in both clinical use (Russia) and experimental nootropic settings (Western use). To date, no consistent reports of severe toxicity, organ damage, or dependence have been published.

Largest Safety Dataset:

• Decades of clinical use in Russia with millions of patient-exposures
• Approved for pediatric use (age 3+) in Russia (Minisem brand)
• Included on Russian List of Vital & Essential Drugs (stringent safety review)

7.2 Common Mild Side Effects

Intranasal Administration:

1. Nasal Irritation (Most Common):

   • Incidence: ~10% of users
   • Symptoms: Dryness, burning, mild discomfort in nasal cavity
   • Severity: Mild; typically resolves within days
   • Management: Reduce dose frequency; ensure proper spray technique

2. Nasal Mucosa Discoloration:

   • Incidence: ~10% (per Russian prescribing information)
   • Description: Transient discoloration of nasal mucosa
   • Clinical Significance: Benign; reversible upon discontinuation

3. Headache:

   • Incidence: 5-8%
   • Severity: Mild to moderate
   • Management: Hydration; dose reduction

4. Nausea:

   • Incidence: 3-5%
   • Timing: Typically during first 2-3 days of use (tolerance develops)

5. Dizziness:

   • Incidence: 3-5%
   • Mechanism: Possible mild orthostatic effects

Subcutaneous Injection:

• Injection Site Reactions: Mild pain, redness (5-10%)
• No systemic side effects specific to SC route beyond those seen with intranasal

7.3 Serious Adverse Events - Rare

Elevated Anxiety (Context-Dependent):

• Incidence: Rare; reported in one trial with 1 mg single intranasal dose in fatigued healthy individuals
• Mechanism: Mild stimulatory effect may exacerbate pre-existing anxiety
• Contraindication: Semax not suitable for subjects with anxiety-related disorders (per some researchers)

Blood Glucose Elevation (Diabetics Only):

• Incidence: ~7.4% of diabetic patients
• Magnitude: Mild increases in blood glucose
• Mechanism: Possible melanocortin receptor-mediated effects on glucose metabolism
• Management: Monitor blood glucose closely; adjust diabetes medications as needed

No Reports of:

• Severe allergic reactions (anaphylaxis)
• Organ toxicity (liver, kidney, cardiac)
• Hematological abnormalities
• Dependence or withdrawal syndrome

7.4 Contraindications

Absolute Contraindications:

1. Diabetes Mellitus (Uncontrolled):

   • Semax may increase blood sugar levels
   • Use with caution; requires close glucose monitoring

2. Pregnancy and Breastfeeding:

   • Insufficient research on fetal/infant safety
   • Avoid use unless explicitly approved by physician

3. Anxiety Disorders:

   • Mild stimulatory effect may worsen anxiety
   • Consider alternative nootropics (e.g., Selank, which has anxiolytic properties)

4. Acute Psychotic Disorders:

   • Dopaminergic modulation may exacerbate psychosis
   • Contraindicated in schizophrenia, acute mania

Relative Contraindications:

• Liver or Kidney Disease: No safety data in these populations; use with caution
• Cardiovascular Disease: Limited data; theoretical concern about dopaminergic activation in unstable cardiac patients

7.5 Drug Interactions - Comprehensive

General Principle: Semax affects dopaminergic and serotonergic systems, so combining it with other drugs influencing these neurotransmitters requires careful management to avoid amplified effects or adverse interactions.

Prescription Medications

Other Nootropic Compounds (Stacking)

Supplements

Foods/Timing Interactions

Drug Interaction Summary Table

7.6 Long-Term Safety - Unknown in Western Populations

Russian Data:

• Decades of clinical use suggest low long-term risk
• However: Russian pharmacovigilance systems differ from Western standards; under-reporting possible

Concerns for Chronic Western Use:

• Lack of long-term RCTs: No Western studies beyond 30-day duration
• Immunogenicity: Unknown risk of anti-Semax antibody formation with chronic use
• Neuroplasticity Overload: Theoretical concern that chronic BDNF elevation could disrupt homeostatic plasticity (no evidence)

Recommendation: Cycle Semax (e.g., 30 days on / 7-14 days off) to minimize unknown long-term risks.

8. Bloodwork Impact & Monitoring

8.1 Expected Marker Changes

Direct Biomarker Effects:

Neurotransmitter Metabolites (Research/Specialized Testing):

Standard Labs (Generally Unaffected):

8.2 BDNF Testing - Detailed Guide

Overview: BDNF (Brain-Derived Neurotrophic Factor) testing is emerging but not yet standardized. It represents the most relevant biomarker for tracking Semax efficacy.

Testing Methods:

Important Caveats:

• Serum BDNF is largely released from platelets during clotting, which introduces variability
• Results vary significantly between laboratories and collection methods
• No standardized reference ranges exist
• Practical utility is limited for routine clinical monitoring

If Testing BDNF:

• Use the same laboratory for baseline and follow-up tests
• Standardize collection conditions (time of day, fasting status)
• Interpret trends rather than absolute values
• Consider it a research/optimization tool, not a clinical diagnostic

8.3 Cognitive Assessments (Functional Monitoring)

Since BDNF testing is limited, functional cognitive assessments provide practical monitoring alternatives:

Standardized Cognitive Tests:

Recommended Assessment Schedule:

Subjective Monitoring (Self-Assessment):

Track daily on a 1-10 scale:

• Mental clarity/focus
• Memory recall
• Processing speed (how quickly you "get" things)
• Verbal fluency
• Motivation/drive
• Mood
• Anxiety level (watch for increases)
• Energy without stimulant feeling

8.4 Monitoring Schedule

Standard Cycle (30 days):

Diabetic Patients - Enhanced Monitoring:

8.5 Red Flags in Labs & Symptoms

8.6 Labs + Symptoms Integration

8.7 Marker-Based Dose Adjustment

Adjustment by Baseline Markers:

Adjustment by Response Markers:

9. Administration and Practical Application

8.1 Intranasal Spray Optimization

Preparation:

1. Clear Nasal Passages: Gently blow nose before administration
2. Prime Pump: New bottles require 3-5 pumps to prime (discard these doses)
3. Shake Bottle: Ensure homogeneous solution

Technique:

1. Head Position: Tilt head slightly forward (NOT backward)
   • Reason: Prevents solution from draining into throat
2. Nostril Selection: Alternate nostrils for each dose
3. Insertion: Insert spray nozzle into nostril; aim toward outer nasal wall (not septum)
4. Actuation: Press pump while inhaling gently through nose
5. Post-Spray: Sniff lightly to distribute solution
   • Do NOT sniff forcefully (may push solution into sinuses)
6. Wait: Remain upright for 1-2 minutes after administration

Common Errors:

• Tilting head backward: Causes solution to drain into throat (reduced bioavailability)
• Forceful sniffing: Pushes solution past olfactory region (reduced CNS uptake)
• Immediate nose blowing: Removes solution before absorption

8.2 Enhancing CNS Bioavailability

Optimal Timing:

• On Empty Stomach: Intranasal absorption is not significantly affected by food, but some users report enhanced subjective effects when fasted
• Avoid Nasal Congestion: Decongestants or nasal saline rinse prior to administration may improve absorption if congested

Synergistic Practices:

• Hydration: Adequate water intake supports mucosal health and absorption
• Nasal Health: Address chronic rhinitis or sinusitis to optimize mucosal absorption surface

8.3 Cycling Strategies

Rationale for Cycling:

• Receptor Sensitivity: Prevent potential downregulation of melanocortin or neurotrophic receptors
• Cost Management: Semax is expensive; cycling reduces long-term financial burden
• Safety: Minimize unknown long-term risks in absence of chronic safety data

Recommended Cycles:

Standard Cycle:

• 30 days on / 7 days off (total cycle: 37 days)
• Suitable for general cognitive enhancement

Intensive Cycle:

• 60 days on / 14 days off
• For therapeutic applications (e.g., post-concussion recovery)

Acute Intervention:

• 3-5 days on / as needed
• For mental exhaustion, exam preparation, high-stress periods

8.4 Stacking with Other Nootropics

Semax + Selank (Common Russian Stack):

• Rationale: Semax (dopaminergic, stimulating) + Selank (GABAergic, anxiolytic)
• Protocol: Semax 300 mcg + Selank 300 mcg intranasal, 2x daily
• Benefit: Balanced cognitive enhancement + anxiety reduction
• Evidence: Anecdotal; no clinical trials of combination

Semax + Racetams (Piracetam, Noopept):

• Rationale: Semax upregulates BDNF; racetams enhance cholinergic transmission
• Protocol: Semax 600 mcg/day + Piracetam 1,600 mg 3x/day
• Caution: Overlapping neuroprotective mechanisms may not provide additive benefits

Semax + Modafinil:

• Rationale: Synergistic dopaminergic activation
• Caution: May cause overstimulation; start with low doses of each

10. Protocol Integration

10.1 The Semax + Selank Stack (Detailed Protocol)

This is the most well-established nootropic peptide combination, commonly used in Russian clinical practice and by Western biohackers. It addresses the "stress-cognition axis" by combining cognitive enhancement with anxiolytic support.

Rationale:

• Semax: Dopaminergic activation, BDNF upregulation, cognitive enhancement (focus, memory, processing speed)
• Selank: GABAergic modulation, anxiolytic effects, stress resilience
• Synergy: Selank buffers the potential overstimulation from Semax while both support complementary aspects of cognitive performance

Protocol Options:

Option A: Simultaneous Dosing

Total Daily: Semax 600 mcg + Selank 600 mcg

Option B: Staggered Dosing (Preferred for Sensitive Individuals)

Total Daily: Semax 400-600 mcg + Selank 600-1000 mcg

Option C: Subcutaneous Administration

Cycling for Semax + Selank Stack:

• Standard: 30 days on, 7 days off (both compounds)
• Extended: 60 days on, 14 days off (for therapeutic use)
• Note: Selank has shorter recommended cycle (10-14 days in Russian guidelines), but many users run it concurrently with Semax

When to Expect Effects:

Research Support: A functional connectivity MRI study in 52 healthy participants assessed Semax and Selank effects on brain networks. Resting-state fMRI was performed before, 5 minutes after, and 20 minutes after injection. Results showed distinct but complementary effects on amygdala (anxiety regulation) and dorsolateral prefrontal cortex (executive function).

10.2 Timing Protocols

Time-of-Day Optimization:

Meal Timing:

• Intranasal: Food does not affect absorption; can dose with or without meals
• Subcutaneous: Generally unaffected by food; some prefer fasted for consistent absorption

Activity Timing:

10.3 Integration with Other Compounds

If Also Taking:

10.4 Integration with Lifestyle Pillars

10.5 Sample Weekly Protocol (Cognitive Enhancement Goal)

Monday - Friday (Work Days):

Saturday - Sunday (Optional Reduced Protocol):

• Option 1: Continue at reduced dose (50%)
• Option 2: Skip weekends (mini-break)
• Option 3: Full dose if cognitively demanding activities planned

Cycle Duration: 4 weeks on, 1 week off Quarterly Check: Cognitive assessment, labs (if indicated)

10.6 Sample Weekly Protocol (Post-Concussion/TBI Recovery)

Daily (Under Medical Supervision):

Total Daily Semax: 2000-4000 mcg (2-4 mg) - consistent with Russian stroke protocols Cycle Duration: 10-14 days initially; may repeat after 10-20 day break Monitoring: Neurological assessment, cognitive testing at baseline and end of cycle

11. Storage and Stability

9.1 Lyophilized Powder

Storage Conditions:

• Temperature: -20°C (freezer storage) for long-term stability
• Alternative: 2-8°C (refrigerator) acceptable for <12 months
• Stability: 24-36 months at -20°C when stored properly
• Light Exposure: Protect from light (use amber vials)

Degradation Indicators:

• Discoloration (yellowing)
• Clumping (moisture absorption)

9.2 Reconstituted Solution (Subcutaneous Use)

Storage Conditions:

• Temperature: 2-8°C (refrigerator) ALWAYS
• Stability: 14-21 days with bacteriostatic water
• Container: Keep in original sterile vial with rubber stopper

Degradation Signs:

• Cloudiness or particulate matter
• pH change (solution should remain neutral)

9.3 Intranasal Spray (Pharmaceutical Formulation)

Unopened Bottles:

• Store at 2-8°C (refrigerator)
• Shelf life: 24 months (per Russian pharmaceutical standards)

Opened Bottles:

• Refrigerate at 2-8°C
• Use within 30 days of opening
• Discard after 30 days even if solution remains clear

Do NOT:

• Freeze intranasal spray bottles (freezing disrupts solution homogeneity)
• Store at room temperature for prolonged periods (>24 hours)

9.4 Stability Advantage

Pro-Gly-Pro (PGP) Stabilization: The C-terminal PGP tripeptide confers enhanced stability compared to native ACTH(4-10):

• Native ACTH(4-10): Half-life ~5-10 minutes
• Semax (with PGP): Half-life ~1-2 hours (10-fold improvement)

This stability allows for practical intranasal formulation and twice-daily dosing.

11. Product Cross-Reference

11.1 Core Peptides Product Availability

Semax Product:

Dosage Supply Calculation (Subcutaneous Use):

• 25 mg vial at 500 mcg/dose: 50 doses (25-50 days at 1-2x/day dosing)
• 25 mg vial at 1,000 mcg/dose: 25 doses (12-25 days at 1-2x/day dosing)

Cost per Day:

• At 1,000 mcg/day: $2.52 per day
• At 500 mcg/day: $1.26 per day

11.2 Russian Pharmaceutical Products (Not Available in USA)

Semax 0.1% Intranasal Drops:

• Concentration: 1 mg/mL
• Bottle Size: 3 mL (3 mg total)
• Dosage: 2-3 drops per nostril (200-300 mcg per administration)
• Manufacturer: Peptogen LLC (Russia)

Semax 1% Intranasal Drops:

• Concentration: 10 mg/mL
• Bottle Size: 3 mL (30 mg total)
• Dosage: 2-3 drops per nostril (2,000-3,000 mcg per administration)
• Indication: Ischemic stroke, severe cognitive impairment

Minisem (Pediatric Formulation):

• Concentration: 0.1% (1 mg/mL)
• Indication: Attention disorders in children age 3+

11.3 Product Quality Considerations

Third-Party Testing (Essential for Grey Market Products):

• HPLC Purity: Should be >95% (pharmaceutical grade >98%)
• Mass Spectrometry: Confirm MW = 813.9 Da
• Amino Acid Analysis: Verify Met-Glu-His-Phe-Pro-Gly-Pro sequence
• Endotoxin Testing: <10 EU/mg for injectable use
• Sterility: Confirm sterile filtration (0.22 micron)

Red Flags:

• No Certificate of Analysis (CoA) provided
• Suspiciously low pricing (<$50 per 25 mg vial)
• Poor reconstitution clarity (cloudiness indicates impurities)
• Vendor cannot provide batch-specific testing data

Verification: Request CoA with:

1. HPLC chromatogram showing purity
2. Mass spectrum confirming MW 813.9 Da
3. Endotoxin test results
4. Batch number and manufacturing date

12. References & Citations

1. Inozemtseva LS, Karpenko MN, Dolotov OV, et al. "Comparison of the temporal dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action." Journal of Molecular Neuroscience 2009; 38(3): 256-261. PubMed: 19662538

2. Eremin KO, Kudrin VS, Saransaari P, et al. "Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents." Neurochemical Research 2006; 31(2): 173-183. Link

3. Filippenkov IB, Stavchansky VV, Denisova AE, et al. "The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis." BMC Genomics 2014; 15: 228. PMC Free Article: PMC3987924

4. Gudasheva TA, Povarnina P, Logvinov IO, et al. "Semax, a synthetic regulatory peptide, affects copper-induced Abeta aggregation and amyloid formation in artificial membrane models." ACS Chemical Neuroscience 2022; 13(3): 359-372. PMC Free Article: PMC8855339

5. Gusev EI, Skvortsova VI. "Investigation of mechanisms of neuro-protective effect of semax in acute period of ischemic stroke." Zhurnal Nevrologii i Psikhiatrii Imeni SS Korsakova 1999; 99(5): 12-18. PubMed: 10358912

6. Russian Clinical Trial. "The efficacy of semax in the treatment of patients at different stages of ischemic stroke." ResearchGate 2018. Link

7. Inozemtseva LS, Karpenko MN, Zolotarev YA, et al. "Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II on male rats in a model of chronic unpredictable stress." European Journal of Pharmacology 2024; 981: 176872. Link

8. Alzheimer's Drug Discovery Foundation. "Semax Cognitive Vitality For Researchers." 2024. PDF Report

9. Swolverine. "Semax Dosing Guide: Protocols, Benefits, and Safety." 2025. Swolverine Blog

10. MedX. "Are Semax and Selank Safe? In-depth Analysis of Safety Profile." 2024. MedX Article

11. Semax - Wikipedia. Wikipedia Entry - Comprehensive overview with multiple primary source citations.

12. PubChem. "ACTH (4-7), Pro-Gly-Pro (Semax)." Compound ID: 9811102. PubChem Database

13. World Anti-Doping Agency. "Prohibited List 2025." WADA Prohibited List - Semax not currently listed.

14. U.S. Food and Drug Administration. "FDA Statement on Peptide Compounding." 2023. FDA Website

15. Peptide Initiative. "Semax: How It Works - ACTH Analog Mechanism." 2024. Peptide Initiative

Document Version: 1.0 Last Updated: December 2025 Disclaimer: This document is for educational and informational purposes only. Semax is not FDA-approved for use in the United States and should not be used for medical treatment without proper clinical oversight. Always consult qualified healthcare providers before using investigational peptides.